In this study, we used qualitative and quantitative methods, including highly-sensitive D-PCR, to assess the EGFR T790M mutation in plasma DNA samples from patients with advanced NSCLC before and after EGFR-TKI therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.